Pfizer cancer drug Ibrance higher sales beat Q3 profit estimates Medical Dialogues Bureau30 Oct 2019 9:30 AM ISTPfizer said it expects to earn between $2.94 per share and $3.00 per share, up from a prior estimate of $2.76 to $2.86. Analysts on average were...
Pfizer quarterly profit in line, touts pipeline of future products Medical Dialogues Bureau31 Jan 2019 9:05 AM ISTOn a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would...
Pfizer, Novartis agree UK price cuts for new breast cancer drugs Ruby Khatun Khatun17 Nov 2017 9:45 AM ISTLONDON: Pfizer and Novartis have agreed to price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely...
Novartis takes fight to Pfizers Ibrance with new Kisqali data Ruby Khatun Khatun10 Nov 2017 10:17 AM ISTZURICH: New data from Novartis's breast cancer drug Kisqali underscored its effectiveness in pre-menopausal women, the Swiss drugmaker said, amid...
Lilly takes on Pfizer, Novartis with new breast cancer drug data Ruby Khatun Khatun12 Sept 2017 10:01 AM ISTNEW YORK/MADRID: Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its...
